IXICO PLC
("IXICO" or
the "Company")
US Client Clinical Trial
Contract Win
10 December
2024 - London, UK. IXICO plc (AIM: IXI,
"IXICO" or "the Company") a global leader in neuroscience imaging, using its AI-driven platform to help
advance therapy research in neurological disorders, today announces
that it has signed a contract with a new US
headquartered client to provide imaging services for a Phase 2
Huntington's Disease clinical trial. The contract value, to be
delivered over approximately 2.5 years, is worth over £0.5 million
to IXICO.
Huntington's Disease is a rare,
hereditary neurodegenerative disorder that leads to the progressive
breakdown of nerve cells in the brain, affecting motor skills,
cognitive function, mood, and emotional well-being.
The contract award reinforces
IXICO's sustained positive commercial momentum, as highlighted in
the Company's FY24 Final Results, and aligns with its strategic
pillars of 'Innovate, Lead, Scale' to drive expansion and growth.
Throughout 2024, IXICO has also secured additional clinical trial
contracts across key therapeutic areas, including Huntington's
Disease, Parkinsonian Disorders, and Alzheimer's
Disease.
Bram Goorden, CEO of IXICO, commented:
"We are
delighted to announce our involvement in this Phase 2 clinical
trial, which aims to address the urgent need for effective
treatments for Huntington's disease. This contract further
demonstrates IXICO's expertise in supporting neurodegenerative
disease trials, reinforcing our role as a trusted partner for
sponsors. Through this work we are proud to continue our support of
the Huntington's Disease community, in collaboration with our
sponsor, working towards a breakthrough in this challenging
field."
Ends
The information contained within this announcement is deemed
by the Company to constitute inside information as stipulated under
the UK version of the EU Market Abuse Regulation 596/2014 which is
part of UK law by virtue of the European Union (Withdrawal) Act
2018, as amended and supplemented from time to time. Upon the
publication of this announcement, this inside information is now
considered to be in the public domain.
Further information:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Bram Goorden, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets
Limited (Nominated Adviser
and
Sole Broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Nigel Birks/Harriet Ward (Corporate
Broking)
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
|
|
|
|
| |
About IXICO www.IXICO.com
IXICO is dedicated to delivering
insights in neuroscience to help transform the advancement of
investigational therapies for neurological diseases, such as
Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to
advance medicine and human health by turning data into clinically
meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all
phases of CNS clinical research. IXICO's goal is to be a leading
advocate of artificial intelligence in medical image
analysis.
IXICO has developed and deployed
breakthrough data analytics, at scale, through its remote access
technology platform, to improve the return on investment in drug
development and reduce risk and uncertainty in clinical trials for
the Company's pharmaceutical clients.